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ABSTRACT: Whereas urine and blood are typically targeted in clinical research, saliva represents an interesting alternative as its 
intrinsic metabolome is chemically diverse and reflective for various biological processes. Moreover, saliva collection is easy and 
non-invasive, which is especially valuable for cohorts in which sample collection is challenging, e.g. infants and children. With this 
rationale, we established a validated UHPLC-HRMS method for salivary metabolic profiling and fingerprinting. Hereby, 450 L of 
saliva was centrifuged and passed over a 0.45-m polyamide membrane filter, after which the extract was subjected to 
chromatographic analysis (HSS T3 column) and Q-ExactiveTM Orbitrap-MS. For the majority of the profiled metabolites, good 
linearity (R2 ≥ 0.99) and precision (coefficient of variance ≤ 15%) was achieved. The fingerprinting performance was evaluated based 
on the complete metabolome (11,385 components), whereby 76.8% was found compliant with the criteria for precision (coefficient 
of variance ≤ 30%) and 82.7% with linearity (R2 ≥ 0.99). In addition, the method was proven fit-for-purpose for a cohort of 140 
adolescents (6-16 years, stratified according to weight), yielding relevant profiles (45 obesity-related metabolites) and discriminative 
fingerprints (Q2 of 0.784 for supervised discriminant analysis). Alternatively, LA-REIMS was established for rapid fingerprinting of 
saliva, thereby using a Nd:YAG laser and Xevo G2-XS QToF-MS. With an acquisition time of 0.5 min per sample, LA-REIMS offers 
unique opportunities for point-of-care applications. In conclusion, this work presents a platform of UHPLC-HRMS and LA-REIMS, 
complementing each other to perform salivary metabolomics.  
Metabolomics is one of the most recent omics technologies, 
whereby the metabolome is mapped as an accurate reflection of 
an individual’s biological phenotype. Hereby, various host-
related biological and external factors, including diet, microbial 
community, stress, lifestyle, etc. are integrated within the 
acquired metabolic fingerprint. This offers unique possibilities 
to characterize an individual’s pathophysiological state, 
allowing the discovery of clinical biomarkers and elucidation of 
metabolic pathways.2 As such, metabolomics has already 
uncovered biologically relevant alterations in e.g. type 2 
diabetes mellitus, cystic fibrosis, and various types of cancers, 
including leukemia, breast, brain and prostate cancer.1-3 
To date, high-resolution mass spectrometry (HRMS) is mostly 
used to perform metabolomics analyses, whereby accurate mass 
measurements (sub-ppm errors) allow for a highly selective and 
sensitive detection of low-abundant metabolites in complex 
biological samples. Moreover, hyphenation with ultra-high-
performance liquid-chromatography (HPLC) provides 
additional selectivity and sensitivity, which enables LC-MS to 
reach high metabolome coverage in metabolic profiling and 
fingerprinting.4,5 Whereas profiling typically aims for the 
identification and absolute quantification of a selection of pre-
defined metabolites, the fingerprinting strategy represents a 
holistic top-down approach with the intention to monitor all 
metabolites present in the biological material under 
investigation.6,7 Both strategies may be implemented for 
biomarker discovery and unraveling of mechanistic pathways, 
involved in health and disease. 
When considering the translation of metabolomics into clinical 
practice, often involving large sample sets and point-of-care 
applications, conventional LC-MS and the associated extensive 
procedures are not very convenient. In this regard, ambient 
ionization constitutes an interesting alternative as sample 
preparation and chromatographic separation are omitted and 
MS-analysis is performed directly on the crude sample.6 One 
type of ambient ionization concerns laser-assisted rapid 
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evaporative ionization MS (LA-REIMS), with the process of 
laser ablation being responsible for the release and ionization of 
metabolites from the sample. As the analysis time (including 
laser ablation and mass analysis) is typically less than one 
minute, this approach offers unique opportunities for rapid 
metabolic fingerprinting, as has already been demonstrated in 
surgical intervention, more specifically intersecting malignant 
tumors.8 Nevertheless, data generated by LA-REIMS are not as 
comprehensive as for LC-MS. Indeed, as there is no 
chromatographic separation, LA-REIMS metabolite 
characterization is solely based on the accurate mass, which 
does not facilitate identification and absolute quantification. 
One element in this regard concerns the merger of isomeric and 
isobaric compounds, evidently compromising metabolome 
coverage. On the other hand, loss and conversion of metabolites 
is very likely to be reduced as no extraction and 
chromatography is performed.  
To date, various biological fluids have been considered for 
metabolomics research in humans, for which especially blood 
plasma and serum, urine, and feces can be listed. Clinical 
applications have been established for all cited biofluids, e.g. 
fecal metabolomics to assess gastro-intestinal disorders 
(including irritable bowel syndrome and inflammatory bowel 
disease), colorectal cancer, and diet-microbiome-metabolome 
interactions, urinary metabolomics to diagnose inborn errors of 
metabolism, kidney dysfunctioning, liver disease, and type 2 
diabetes, and blood metabolomics to research cancer, 
cardiovascular diseases, neurological and endocrine disorders, 
infections, etc.9-12 However, with respect to the collection of 
blood samples, a number of substantial disadvantages can be 
noted; i.e. the invasive collection, need for trained personnel, 
and handling risks. In this context, urine and feces represent 
interesting alternatives, although there is still some 
inconvenience for repeated and on-the-spot sampling, as well as 
with respect to the extraction, which can be quite complex. As 
such, and despite existing diagnostic assays and self-test kits 
may circumvent a number of these issues10, performing 
untargeted discovery-phase metabolomics or targeting 
extensive biomarker signatures in these biofluids still 
encounters practical difficulties. In this regard, the above-cited 
shortcomings are much less applicable for saliva, being the 
most accessible and readily available bio-fluid in humans. 
Although saliva is primarily composed of water, this matrix is 
chemically complex, containing mucus, digestive enzymes, 
growth factors, hormones, cytokines, immunoglobulins, anti-
bacterial and anti-viral peptides, but also bacterial and viral 
cells including their metabolites13. Being produced by the 
salivary glands and the gingival sulcus, saliva has been 
recognized to play a vital role in food digestion, protection 
against harmful microorganisms and lubrication of the oral 
cavity. In addition, saliva is involved in taste-bud growth, 
wound healing and pain numbing. Moreover, as many 
metabolites can pass through blood passively or actively, saliva 
was also found to reflect processes from outside the oral cavity. 
Even more, saliva metabolites have been noted to parallel 
metabolic alterations that occur in blood, and may thus reflect 
many pathophysiological and nutritional changes, as well as 
exposure to medication and environmental factors.14 In line 
with these observations, saliva has become a common tool for 
diagnosis of various cancers, diabetes, Cushing’s disease, 
hepatitis, etc. 13,15-17. Although saliva represents an interesting 
matrix, current studies mostly target specific metabolites or 
classes that are already known to be involved in a certain 
disease state or medication action, thus profiling only a small 
part of the saliva metabolome.13,17-21 Therefore, untargeted 
fingerprinting will offer new perspectives in both fundamental 
and translational metabolomics.
The objective of this study was to establish a validated 
analytical platform of comprehensive UHPLC-HRMS and 
rapid LA-REIMS for salivary metabolomics, inclosing both 
targeted profiling and untargeted fingerprinting. With respect to 
the profiling, it was mainly intended to cover an increased 
number of chemical classes compared to the currently available 
salivary profiling methods.13,17-21 The abilities of salivary 
metabolomics were demonstrated in a cohort of adolescents that 
were stratified according to weight, whereby the collected 
saliva samples were subjected to UHPLC-HRMS and LA-
REIMS analysis to define the pathophysiological state and 
relevant metabolic alterations. As such, presenting an analytical 
platform that is validated and fit-for-purpose, salivary 
metabolomics may find its way in clinical practice, for both in-
depth mechanistic elucidations as well as point-of-care 
applications.  
MATERIALS AND METHODS
Analytical Standards and Reagents
Analytical and internal standards that were used for LC-MS and 
LA-REIMS analysis are listed in Table S1. Stock solutions were 
prepared at a concentration of 1 mg.mL-1, using either methanol 
or ultrapure water (0.055 μS·cm-1, delivered through a purified 
water system (VWR International, Belgium)). These and the 
derived working solutions were stored at -20 °C in amber glass 
vials. Solvents used for analysis were of LC-MS grade and from 
VWR International (Belgium) or Fisher Scientific (USA).  
Biological Samples
In this study, saliva was obtained from adolescents (6-16 years) 
through a standardized protocol, whereby samples were 
collected via Salivette synthetic swabs and Cryovials (Sarstedt, 
Germany) at Ghent University Hospital in the presence of 
trained staff members. Saliva was collected between 4.30 and 
5.30 p.m., with the participants being restrained from any food 
or drinks (except water) for at least 3 h prior to collection and 
allowed to brush their teeth in the morning only. Smoking or 
alcohol use was not permitted during the whole day. Samples 
were stored at -80 °C. The study was approved by the Ethical 
Committee of Ghent University Hospital EC UZG 2017/0527.
Salivary metabolomics by UHPLC-HRMS
Optimization of Salivary Extraction. Generic extraction was 
optimized through a design of experiments, for which JMP 12 
software was used (SAS, UK). First, a Chakravarty fractional 
factorial screening design (FFD) was established with 21 
experiments (3 center points) to assess four factors: 
centrifugation (no centrifugation, 4,200 or 17,000 x g), volume 
of saliva (300 to 1500 µL), dilution factor (0.1 to 1), and 
filtration (no filtration or usage of a polyvinylidene difluoride 
(PVDF) membrane filter, 13 mm diameter, 0.22 µm pore size 
(Merck, Ireland)). The effect of each factor was statistically 
evaluated based on the metabolome coverage (i.e. total number 
of detected components) as well as the summarized normalized 
peak area of those metabolites that were detected upon targeted 
profiling (n = 81) (Table S1). With respect to the latter, 
identification at Tier 1 was achieved based on the accurate mass 
(m/z-value, considering the molecular ion and 13C isotope) and 
the retention time relative to that of an internal standard, all with 
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reference to an authentic standard.22 In a second phase, response 
surface modeling (RSM) with 16 experiments (3 center points) 
was applied to optimize the significant quantitative factors, i.e. 
the centrifugation speed (4,200 to 17,000 x g), volume of saliva 
(300 to 500 L), and dilution factor (0.1 to 1). Statistical 
evaluation was based on the metabolome coverage and 
summarized normalized peak area of detected target 
metabolites (n = 54) (Table S1). In addition, also aspects of 
practical feasibility were taken into account, i.e. a filtration step 
appeared inevitable to prevent clogging of the LC-column. In 
this regard, the PVDF filter was tested against a polyamide 
membrane filter (25 mm diameter, 0.45 µm pore size, 
Macherey-Nagel, Germany) and Amicon® ultra-centrifugal 
filter (30 kDa, Merck, Ireland).
Final Salivary Extraction Protocol. The optimized protocol 
for polar metabolomics used 450 µL of saliva, which was 
pipetted into a 1.5-mL Eppendorf tube. After adding 10 L of 
internal standard mixture (25 ng.µL-1 D-valine-d8 and L-
alanine-d8), the solution was shortly vortexed and centrifuged 
for 5 min at 17,000 x g (room temperature). Next, the 
supernatant was collected using a 1-mL syringe with needle and 
passed over a polyamide membrane filter (25 mm diameter, 
0.45 µm pore size, Macherey-Nagel, Germany). Finally, 150 µL 
of the undiluted extract was transferred to an LC-vial with glass 
insert.
UHPLC-HRMS Analysis. UHPLC-HRMS analysis of saliva 
extract was based on the validated methods of Vanden Bussche 
et al. (2015) for feces and De Paepe et al. (2018) for urine and 
plasma.4,23 For chromatographic separation, a Dionex Ultimate 
3000 XRS UHPLC system (Thermo Fisher Scientific, USA) 
was used, which was equipped with an Acquity HSS T3 C18 
column (1.8 µm, 150 x 2.1 mm) (Waters, UK) that was kept at 
45 °C. The binary solvent system consisted of ultrapure water 
(A) and acetonitrile (B), both acidified with 0.1% formic acid. 
Using a flow rate of 0.4 mL·min-1, the following gradient was 
applied (solvent A, v/v): 0-1.5 min at 98%, 1.5-7.0 min from 
98% to 75%, 7.0-8.0 min from 75% to 40%, 8.0-12.0 min from 
40% to 5%, 12.0-14.0 min at 5%, 14.0-14.1 min from 5% to 
98%, followed by a re-equilibration step of 4.0 min. The sample 
injection volume was 10 L. For mass analysis, a Q-ExactiveTM 
mass spectrometer was employed (Thermo Fisher Scientific, 
USA), which was equipped with a heated electrospray 
ionization (HESI-II) source that was operated in polarity 
switching mode and positioned in 0/B/1. Instrumental 
parameters included a sheath, auxiliary and sweep gas flow rate 
of, respectively, 50, 25 and 5 arbitrary units (au), heater and 
capillary temperature of, respectively, 350 and 250 °C, S-lens 
RF level of 50%, and a spray voltage of 3 and 2 kV for positive 
and negative ionization mode, respectively. The m/z scan range 
was set from 53 to 800 Da for both ionization modes, the 
automatic gain control target was 1 x 106 ions, the maximum 
injection time was 70 ms and the mass resolution was 140,000 
FWHM (1 Hz). 
Quality Assurance. To ensure accurate mass measurements 
(i.e. mass deviations ≤ 3 ppm), instrument calibration was 
performed with ready-to-use calibration solutions according to 
the manufacturer’s guidelines (Thermo Fisher Scientific, USA). 
In addition, the operational conditions of the device were 
evaluated by injecting a standard mixture of 300 target 
metabolites (1 ng·L-1) (Table S1) at the beginning and end of 
every sequence. For analysis of large batches, quality control 
(QC) samples were included, which were made from a pool of 
all biological samples. QC extracts were repeatedly injected at 
the beginning of the analytical sequence for conditioning of the 
system and in between the analyzed biological samples (two 
QCs after every ten samples) to allow correcting for 
instrumental drift.  
Method Validation. Linearity and precision were assessed in 
accordance to Naz et al. (2014), FDA guidelines (2018), and 
Ulaszewska (2019)5,24,25, through a targeted and untargeted 
evaluation. For the targeted approach, 32 endogenously present 
metabolites were carefully chosen in order to attain adequate 
representation of various chemical classes (Table S2). 
Linearity was assessed by serial dilution of a QC extract with 
artificial saliva (20 mM sodium dihydrogen phosphate, pH 7.4), 
thereby establishing a 9-point calibration curve with dilution 
factors ranging from 1 (no dilution) to 100. Evaluation of the 
linearity was based on the determination coefficient (R2). For 
the untargeted approach, 9-point calibration curves (n=3) in 
ultrapure water were used, thereby performing calculations only 
for components recovered across all dilutions. 
Precision analysis comprised evaluation of the instrumental, 
intra- and inter-day assay precision, which were all expressed 
as the coefficient of variance (CV, %). The instrumental 
precision was evaluated by the sequential injection of a same 
QC extract ten times (assay performed in triplicate). The intra-
day assay precision was assessed by considering a QC sample 
that was extracted nine times in parallel under repeatable 
experimental conditions, by the same analyst. For the intra-
laboratory reproducibility, a QC sample was extracted 18 times, 
half of which were extracted by a second analyst on a different 
day.  
Data Processing. Targeted processing of the HRMS full-scan 
data, including metabolite identification and quantification, was 
performed using XCalibur 3.0 software (Thermo Fisher 
Scientific, USA). Identification was based on three parameters, 
whereby congruence with the analytical standard was required, 
i.e. the m/z-value of the molecular ion (mass deviation ≤ 5 ppm), 
the C isotope pattern (13C/12C isotope ratio, compliant with CD 
2002/657/EC) and a retention time relative to that of the internal 
standard (maximum deviation of 2.5%).25 With respect to the 
untargeted data analysis, SIEVETM 2.2 (Thermo Fisher 
Scientific, USA) was applied to process data as acquired during 
method development and validation. Compound DiscovererTM 
2.1 (Thermo Fisher Scientific, USA) was used for analysis of 
full-scan data from the clinical study, allowing to process the 
data from the positive and negative ionization mode together. 
Both software programs applied automated peak alignment, 
peak extraction, deconvolution, blank peak filtering, and noise 
removal. Detected features were characterized by the m/z-value, 
retention time and peak intensity. Clusters of related features 
(i.e. components) were established, considering amongst others 
the presence of various ionization adducts and isotopes. The 
main software settings are presented in Table S3. 
Salivary metabolomics by LA-REIMS
Final Protocol for Saliva Pre-treatment. Prior to LA-REIMS 
analysis, 450 L of saliva was pipetted in a 1.5-mL Eppendorf 
tube and centrifuged for 5 min at 17,000 x g (room 
temperature). Next, the supernatant was collected using a 1-mL 
syringe with needle and passed over a polyamide membrane 
filter (25 mm diameter, 0.45 m pore size, Macherey-Nagel, 
Germany). A volume of 50 L filtrate was transferred to a glass 
microscope slide for LA-REIMS analysis. Although it was 
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intended to limit sample pre-treatment to the absolute minimum 
for LA-REIMS applications, inclusion of the filtration step was 
needed to address some practical issues (i.e. clotting within the 
saliva sample upon laser ablation, most likely due to protein 
precipitation). 
Optimization of LA-REIMS Analytical Method. Relevant 
parameters for LA-REIMS analysis were optimized by a design 
of experiments, using the software program JMP 12 (SAS, UK). 
First, a D-optimal FFD (36 runs, 6 center points) was performed 
in duplicate for both the positive and negative ionization mode 
to assess the significance of various factors (with indication of 
the tested value range); the laser pulse time (165 to 220 s), 
cone voltage (20 to 100 V), heater bias voltage (10 to 50 V), 
scan time (0.1 to 1 s·scan-1), and isopropanol solvent flow rate 
(0.05 to 0.20 mL·min-1). The effect of each factor was evaluated 
based on the absolute metabolome coverage (i.e. number of 
detected ions) and detection sensitivity (total ion abundance, 
TIC), thereby considering separate m/z intervals (i.e. from 50 to 
250 Da, from 250 to 500 Da, from 500 to 750 Da, from 750 to 
1000 Da, and from 1000 to 1200 Da) to warrant the holistic 
nature of the analytical method. Following the FFD-based 
screening, a central composite RSM design was applied to 
define the optimal settings for the significant factors. For both 
ionization modes, all factors were incorporated in the RSM 
design (29 runs, 3 center points), whereby different ranges were 
tested for each mode; laser pulse time (165 to 220 s for 
negative ionization, 165 to 195 s for positive ionization mode), 
cone voltage (15 to 100 V for negative mode, 20 to 70 V for 
positive mode), heater bias voltage (10 to 70 V for both modes), 
scan time (0.1 to 0.8 s·scan-1 for negative mode, 0.5 to 1 s·scan-1 
for positive mode), and isopropanol solvent flow rate (0.05 to 
0.30 mL·min-1 for negative mode, 0.05 to 0.15 mL·min-1 for 
positive mode). Evaluation of the RSM design was based on the 
metabolome coverage and sensitivity, considering various m/z-
intervals. Additional tests (full factorial designs, ≥ three 
technical replicates) were conducted to further optimize the 
heater bias.  
Final LA-REIMS Analytical Method. The system used for 
laser ablation was an OpoletteTM HE2940 pump laser 
(OPOTEK LLC, USA) that consisted of a Nd:YAG laser, 
steering optics, optical parametric oscillator (fixed at 2940 nm), 
and wavelength separation optics. Transmission of the laser 
energy to the sample was achieved through free space optics, 
including a series of metallic-coated mirrors (OptoSigma, 
France) and a plano-convex lens (Thorlabs GmbH, Germany). 
Main operational settings for the laser pumping system were a 
pulse time of 180 and 165 s for negative and positive 
ionization mode, respectively, and a repetition rate of 20 Hz. 
The total exposure time per burn (i.e. the period of laser 
ablation) was about 3 s and at least two burns per sample were 
generated. The aerosol produced was transferred to the REIMS 
platform by a 2.5-m polytetrafluorethylene tubing (1.6 mm 
internal diameter and 3.2 mm outer diameter), which was 
connected to the electrospray REI-interface by means of a T-
shaped piece. A flow of isopropanol, containing the internal 
standards palmitic acid-d31 (5 ng·L-1, [M-H]-) and 1,2-
dimyristoyl-d54-sn-glycero-3-phosphocholine (100 ng·L-1, 
[M+H]+), was provided to ameliorate ionization. The flow rate 
was set at 0.2 mL.min-1 for negative and 0.12 mL·min-1 for 
positive ionization. Full-scan mass analysis was carried out 
using a Xevo G2-XS Quadrupole Time-of-Flight (QToF) mass 
spectrometer (Waters Corporation, UK), applying an m/z scan 
range from 50 to 1200 Da. Main settings included a cone 
voltage of 45 V for negative and 20 V for positive ionization, a 
heater voltage of 70 V for negative and 75 V for positive 
ionization, and a scan time of 0.5 s·scan-1 for both ionization 
modes. The acquisition time was 0.50 min·sample-1. 
Quality Assurance. Prior to LA-REIMS analysis, the 
instrument was calibrated (≤ 1 ppm mass deviation, also 
warranted by lock mass correction) in sensitivity mode 
according to the manufacturer’s guidelines (Waters 
Corporation, UK), thereby using a solution of 0.5 mM sodium 
formate in isopropanol and ultrapure water (90/10, v/v). During 
analysis, instrument performance was monitored based on the 
internal standards’ signal intensities and/or incorporation of 
quality control (QC) samples, which were pooled saliva extracts 
from at least seven persons. For the clinical cohort, ten external 
QC samples were included at the beginning and end of the 
analytical batch and two internal QC samples were inserted 
after every forty runs. 
Data processing. Data from the FFD and RSM designs were 
processed by Abstract Model Builder 1.0.1581.0 (Waters 
Corporation, UK), thereby creating mass bins of 0.1 Da. For the 
clinical study, data were processed using MassLynx® 4.1 
Progenesis Bridge (Waters Corporation, UK), whereby 
adaptive background subtraction, lock mass correction, creation 
of extracted chromatograms for each burn, and separation of 
multiple burns was carried out. Subsequently, the data file from 
the most intense burn was selected and subjected to Progenesis® 
QI 2.3 peak picking (Waters Corporation, UK), applying the 
automatic sensitivity mode with a default value of 3.  
Multivariate analysis 
Multivariate statistical analysis of UHPLC-HRMS and LA-
REIMS data was achieved using SIMCA 14.1 software 
(Umetrics AB, Sweden), for which data were pre-processed by 
TIC and QC-normalization, log-transformation, and pareto-
scaling. Principal Component Analysis (PCA-X) was applied to 
visualize natural patterning of samples and identify outliers. 
Supervised modelling was performed, constructing Orthogonal 
Partial Least-Squares Discriminant Analysis (OPLS-DA) 
models. The validity of these models was assessed by cross-
validated analysis of variance (CV-ANOVA, p-value), 
permutation testing (n = 100) and the model characteristics 
R2(X) and R2(Y) for model fit and Q2(Y) for model predictivity. 
Selection of discriminative components or features was based 
on the S-plot (covariance p and correlation corr(p)), Variable 
Importance in Projection (VIP) score, and the Jack-knifed 
confidence interval.
Salivary Metabolomics in a Clinical Context 
To demonstrate the potential of UHPLC-HRMS and LA-
REIMS salivary metabolomics, the established methods were 
implemented in a clinical context of healthy versus unhealthy 
weight (i.e. overweight and obesity). This study was approved 
by the Ethics Committee of Ghent University Hospital (EC 
UZG 2017/0527) whereby 140 adolescents (6 to 16 years, 51% 
girls) were recruited for assembling a biobank of saliva 
samples. A written consent was obtained from the parents and 
children (from the age of 12 years) while verbal assent was 
obtained for younger children. Exclusion criteria included the 
presence of known endocrine or metabolic diseases other than 
overweight or obesity. Furthermore, data on drug use, age, 
tanner stage, sex and physical activity were collected. Adiposity 
classifications were made using BMI z-scores (adjusted BMI 
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for age and sex) following Roelants et al. (2012)26 and extended 
international (IOTF) body mass index cut-offs for thinness, 
overweight and obesity by Cole et al. (2012)27. Weight and 
height were measured by trained staff using a bio-impedance 
instrument (TANITA BC-420 SMA, Tanita Corporation, 
Japan) and stadiometer (Seca 225, SECA, USA), respectively. 
As such, the following classification structure was obtained: 7 
adolescents with underweight, 92 with normal weight, 28 with 
overweight and 13 obese. 
RESULTS AND DISCUSSION
Salivary UHPLC-HRMS Profiling and Fingerprinting.
Optimization of Salivary Extraction. The saliva extraction 
protocol was optimized through a sequential strategy of 
experimental designs, i.e. FFD and RSM, for which the results 
are presented in Table S4. Based on the FFD, centrifugation was 
assigned a significant positive effect (p-value < 0.05) in both 
the targeted and untargeted evaluation, whereby no differences 
were observed between the two centrifugation speeds. 
Implementation of a centrifugation step is typically 
incorporated to reduce clogging of the LC-column, which may 
be caused by the presence of mucus, large proteins, and food 
residues.28 Accordingly, saliva extraction protocols often also 
include filtration for the removal of proteins.13,29 The outcome 
of the FFD indicated no significant effect of the filtration on the 
extraction efficiency in metabolic profiling nor on the 
metabolome coverage in fingerprinting, which allowed 
inclusion of a filtration step to avoid clogging of the LC-
column. With respect to the saliva starting volume, no 
significant differences were observed, although a higher 
volume tended to have a positive impact. On the other hand, 
dilution of the extract was associated with a borderline non-
significant negative effect (p-value of 0.056) for the 
summarized normalized peak areas of the 81 endogenous 
metabolites, selected for targeted evaluation. 
Additional optimization of the quantitative factors was 
performed by RSM, which allowed to determine the optimal 
centrifugation speed, saliva volume and dilution factor. Usage 
of undiluted saliva had a significant positive effect (p-value ≤ 
0.002) on the extraction efficiency, independently from the 
saliva start volume and for both the targeted and untargeted 
approach. This observation was expected as metabolites, 
especially those not directly originating from saliva, but from 
blood or other matrices are usually present in saliva in low 
concentrations.13 With the volume of saliva not having a 
significant effect in the RSM design, it was reasonable to limit 
the amount used. Indeed, as collected samples are always 
precious for multiple testing, it was opted to start the protocol 
with 450 L saliva, which yields a minimum of 150 L extract 
for UHPLC-HRMS analysis. Similar to the results from the 
FFD, the centrifugation speed had no significant effect on the 
RSM outcome, although the effect tended to be positive towards 
the highest speed (17,000 x g). A final element of the extraction 
protocol concerned the kind of filter used. After usage of the 
PVDF filter (0.22 µm pore size), it was experienced that the LC-
column still tended to clog after the consecutive analysis of 
more than 20 samples. Other filters were tested, including a 
polyamide membrane filter (0.45 µm pore size) and a 30 kDa 
Amicon® ultra-filtering centrifugal filter. The polyamide 
membrane filter had a significant positive impact (p-value of 
0.014) on the saliva extraction profiling and fingerprinting 
approach. It was presumed that the Amicon® filter specifically 
binds large proteins, which may hamper the passage of small 
molecules. The polyamide filter with a pore size of 0.45 µm was 
assumed to mainly retain mucus and debris coming from food. 
This implied that the final extract still contained proteins that 
might be subject of protease activity, with potential introduction 
of artefacts. In this regard, low handling temperatures 
(collection of samples on ice, storage at -80 °C, thawing at 4 
°C) and short processing times (ca. 5 min) were considered 
essential to limit the formation of these artefacts, as protease 
activity is limited at low temperatures.
Method Validation. The results from the method validation are 
presented in detail in Table S2 and summarized in Table 1.
Linearity. For the targeted approach, excellent linearity (R2 ≥ 
0.99)24,25 was achieved for 31 endogenous compounds (Table 
S2) whereby this was achieved across the total dilution range 
for 22 metabolites while for 9 metabolites the strongest 
dilutions had to be excluded because of limited sensitivity. This 
was particularly observed for a number of carbohydrates, amino 
acids, and one steroid, whereby their low detection response 
and/or low abundance in saliva are plausible reasons. In 
contrast, one metabolite (L-carnosine) exhibited limited 
linearity (R2 of 0.984), probably due to saturation effects. 
Untargeted evaluation suggested good linearity performance, 
with 82.7% of the 8,134 components having a R2 ≥ 0.90.
Precision. With respect to the precision, the FDA guidelines 
recommend a CV ≤ 15%, except when operating close to the 
limit of detection (CV ≤ 20%). For the targeted analyses (Table 
S2), 25 of the 32 representative compounds had an instrumental 
precision with a CV ≤ 15%, six had a CV ≤ 20% and only one 
metabolite, D-gluconic acid, had a CV above the cited 
thresholds (i.e. CV of 23.6%). Evaluation of the intra-day 
repeatability resulted in 28 metabolites with a CV ≤ 15%, three 
with a CV ≤ 20%, and one with a CV of 25.3% (i.e. L-
carnosine). For the inter-day repeatability, all metabolites had a 
CV ≤ 15%, with the exception of vanillic acid (i.e. CV of 
17.7%). As a result, only for the class of the hybrid peptides 
(represented by L-carnosine), the guidelines for precision were 
not completely met (i.e. a CV-value > 20% was observed). One 
possible explanation may relate to the saturation effects that 
were noted for this metabolite during the linearity evaluation. 
For untargeted fingerprinting, a CV ≤ 30% is generally 
recommended for acceptable precision.22,23,28 For a total of 
11,385 salivary components, the instrumental precision, intra-
assay and inter-day precision were calculated and evaluated 
towards the cited threshold. This resulted in, respectively, 
acceptable precision for 86.6%, 83.0% and 76.8%, of all 
salivary components. These results are very promising as the 
method is capable to obtain a high saliva metabolome coverage 
with a high level of precision.
Table 1. Summary of the UHPLC-HRMS validation for 
successful targeted profiling and untargeted fingerprinting. 
Targeted Untargeted 
Linearity 29/32 (R2 ≥ 0.99) 82.7% (R2 ≥ 0.90)
Precision
   Instrumental 31/32 (CV < 20%), 
25/32 (CV < 15%)
86.6% (< 30%)
   Intra-day 31/32, (CV < 20%), 
28/32 (CV < 15%) 
83.0% (< 30%)
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   Inter-day 32/32 (CV < 20%), 
31/32 (CV < 15%)
76.8% (< 30%)
Salivary Metabolomics in a Clinical Context using UHPLC-
HRMS. Saliva has only recently been implemented in the 
research of various pathophysiological states such as CMV 
infection, cancer, Cushing’s disease, and cystic fibrosis.30,31 The 
non-invasive character and the easiness of collection, even 
multiple times a day makes saliva an interesting matrix for 
research, diagnosis and prognosis. In this regard, this study 
presents a validated UHPLC-HRMS method for salivary 
metabolomics, for which its potential for metabolic profiling 
and fingerprinting was demonstrated in health and disease, i.e. 
obesity.
Profiling of saliva to study obesity. In first instance, it was 
investigated whether our validated salivary profiling approach 
was able to define metabolic perturbations in saliva, underlying 
overweight and obesity in adolescents. Whereas our in-house 
library allowed the profiling of 129 metabolite compounds 
(Table S1) from 18 different classes, 45 of these compounds 
have been reported in literature to be involved in obesity 
metabolism (Table S5). One prominent class encloses the 
amino acids, for which both branched-chain amino acids 
(leucine, isoleucine and valine) and aromatic amino acids 
(phenylalanine, tryptophan, tyrosine and histidine) have been 
linked to weight increase, obesity and even type 2 diabetes. 
More specifically, the phenylalanine-tyrosine-dopamine 
pathway (as defined for saliva) plays an important role in the 
desire to eat and has been linked directly to obesity. In addition, 
salivary tryptophan and kynurenine (Table S5) are involved in 
the serotonin pathway, mediating serotonin levels and as a 
consequence satiety, mood disturbance and depression, all 
being physiological markers of obesity. Another class concerns 
that of the carbohydrates, with their salivary concentration 
levels often being linked to food intake but with mannose being 
hypothesized to play a role in insulin resistance, as a result of a 
defect glycosylation. Also the class of fatty acid esters has been 
described to be involved in obesity and insulin resistance, with 
e.g. methylbutyrylcarnitine being assigned a role in childhood 
obesity. Hereby, a link with an unbalanced mitochondrial fatty 
acid oxidation has been suggested. As such, metabolic profiling 
of saliva offers substantial potential for studies on obesity in 
young children, adolescents and adults, which may lead to the 
discovery of potential biomarkers for obesity and its co-
morbidities. 
Fingerprinting of saliva to study obesity. To demonstrate the 
potential of UHPLC-HRMS for metabolic fingerprinting, we 
analyzed saliva from 41 obese/overweight and 41 healthy 
weight adolescents. Fingerprints covered 9,044 components 
(Figure 1). The associated data matrix was pre-processed by 
TIC- and QC-normalization, whereby only components were 
retained that exhibited a CV ≤ 30% in the set of QC-samples. 
This rendered 6,639 components (not per se representing actual 
metabolites), which were subjected to multivariate statistics. 
Figure 1. Fingerprint of positive (A) and negative (B) component 
ions upon UHPLC-HRMS analysis of saliva from adolescents (n = 
140). Identified metabolites (in-house library) are indicated in bold. 
PCA-X analysis revealed narrow clustering of the QC samples 
(Figure 2) and thus indicated good instrumental stability and 
reliable data acquisition. Moreover, no outliers were observed, 
which was verified based on the Hotelling’s T2 99% confidence 
interval as calculated for the biological samples only (i.e. excl. 
QC samples). However, no patterning according to weight 
status was uncovered, which means that the largest variations in 
the salivary fingerprints were due to aspects that cannot directly 
be related to adiposity classification, such as for example diet, 
gender, tanner stage, and environment. Also, subsequent OPLS-
DA modelling was not able to reveal significant metabolic 
differences, as the model was not compliant with the set 
validation criteria (Q2(Y) < 0.5, p-value > 0.05, and 
inacceptable permutation testing). This may relate to the 
relative low number of cases per study population, which 
hampers the statistical power and the ability to uncover the 
subtle metabolic differences that are underlying the clinical 
condition under investigation. Nevertheless, pre-filtering of the 
data based on the VIP-score (≥ 1) and Jack-knifed confidence 
interval (not across zero) yielded a subset of 295 components 
(of which 7 were identified using our in-house library, Table 
S1) for which significant differentiation according to weight 
status could be established upon PCA-X and OPLS-DA 
modelling (Figure 2). Hereby, a valid OPLS-DA model was 
obtained with an R2(X) of 0.322, R2(Y) of 0.846, Q2(Y) of 
0.726, p-value < 0.001, and good permutation testing. 
Figure 2. PCA-X (A) and OPLS-DA (B) score plot as obtained 
upon UHPLC-HRMS fingerprinting of saliva from normal 
weight (n = 41, blue) and obese/overweight (n = 41, yellow) 
individuals. Grey circles in Figure A represent QC-samples.
Salivary metabolomics by LA-REIMS 
Optimization of LA-REIMS Analytical Method. LA-REIMS 
for rapid fingerprinting of saliva was optimized by means of an 
experimental design, which allowed to efficiently define the 
optimal settings for the various methodological parameters. The 
FFD revealed that the main effects of the solvent and pulse time 
were significant (p-value < 0.01) for both ionization modes, 
whereas the main effect of the cone voltage was also significant 
for the negative ionization mode (p-value < 0.01) (Table S6). In 
addition, evaluation of the first-degree interaction effects 
showed that also the cone voltage (positive ionization) and scan 
time (negative and positive ionization) had a significant impact 
on the metabolome coverage and detection sensitivity (p-values 
< 0.05). Taking into consideration these findings, it was opted 
to evaluate all five factors by the subsequent RSM modelling, 
thereby adjusting the tested range of settings according to the 
preliminary results from the FFD. For the negative ionization 
mode, the RSM indicated significant main effects (p-value < 
0.001) for all factors across the tested ranges, with exception of 
the heater bias (Table S6). However, the latter factor showed 
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significance when evaluating the first-degree interactive effects 
(p-value < 0.05). Optimal values for the scan time (0.5 s·scan-
1), pulse time (180 s), and cone voltage (45 V) were clearly 
expressed through the RSM prediction profiler but the optimal 
setting for the flow rate was noted to vary according to the m/z 
interval. Indeed, lower flow rates (0.05 mL·min-1) seemed to 
improve the ionization efficiency of the low-weight molecules 
(m/z from 50 to 500 Da) whereas higher flow rates (0.25 
mL·min-1) tended to ameliorate ionization of the high-weight 
molecules (m/z from 500 to 1200 Da). A compromise value of 
0.2 mL min-1 was set. Using these final settings, the heater bias 
voltage was further optimized based on a full factorial design 
(testing values of 10, 30, 50, 70, and 90 V). Although no 
significant differences were observed, 70 V seemed to result in 
the best detection sensitivity. For the positive ionization mode, 
the main effect was significant (p-value < 0.05) for all factors 
with exception of the heater bias voltage. Optimal values for the 
scan time (0.5 s·scan-1), pulse time (165 s), and cone voltage 
(20 V) were clearly expressed by the RMS prediction profiler. 
Also here, the optimal setting for the solvent flow rate varied 
according to the m/z interval whereby a compromise value of 
0.12 mL·min-1 was selected. However, lower values (0.05 
mL·min-1) seemed to improve the ionization efficiency of the 
low-weight molecules (m/z from 50 to 500 Da). The heater bias 
was further optimized through a full factorial design (testing 
values of 60, 70, 80, and 90 V), whereby a value of 75 V 
rendered the highest signal intensities, although not being 
significant.
Fingerprinting by LA-REIMS. Metabolic fingerprints as 
acquired by LA-REIMS analysis are depicted in Figure 3, 
whereby the burn TIC signal as well as the underlying acquired 
mass spectrum are presented for each ionization mode. The total 
number of covered ions (features) amounted 13,231, of which 
50.2% were obtained in positive ionization mode. Clustering of 
ions (features) was not performed (i.e. grouping of related 
isotopes and adducts) as the lack of orthogonal separation data 
(e.g. from LC) would result in too many false positive matches. 
It may be noted that LA-REIMS analysis in positive ionization 
seemed to be more sensitive for the low-molecular weight 
metabolites or/and the saliva metabolome contained more low-
molecular weight metabolites that were proton acceptor (e.g. 
H+).
Figure 3. TIC signal (“burn”) as obtained upon LA-REIMS 
analysis of saliva in negative (A) and positive (C) ionization mode. 
Mass spectra for negative and positive ionization (B and D, 
respectively). 
Quality assurance. The analytical performance of LA-REIMS 
was primarily evaluated in terms of the precision, which was 
studied based on the batch of clinical samples (total analysis 
time of about 5 h, covering 246 runs). It should be noted that 
these samples were analyzed in a single continuous batch, 
performing only minimal cleaning, i.e. using a cotton swab that 
was wetted with ethanol to remove saliva splashes from the lens 
(~ every 5 samples). Hereby, the internal and external QC 
samples were subjected to CV-analysis. The external QC 
samples allowed to define the instrumental precision, whereby 
ten sequentially analyzed samples at the end of the sequence 
showed acceptable repeatability, i.e. 87.0% of the negative and 
55.8% of the positive ions (features) showed a CV ≤ 30%. With 
respect to the internal QC samples (indicating the intra-day 
precision), acceptable CV (i.e. ≤ 30%) was obtained for 69.0% 
and 59.5% of the negative and positive ions (features), 
respectively. Based on these findings and the PCA-X score 
plots (Figure 2), which indicated narrow clustering of the 
internal QC samples, LA-REIMS showed excellent ruggedness 
and was proven suited for reliable fingerprinting, especially in 
negative ionization mode, which is in line with Bodai et al. 
(2018).31
Salivary Metabolomics by LA-REIMS in a Clinical Context. 
The performance of LA-REIMS to achieve rapid discriminative 
fingerprinting was evaluated within the clinical cohort, thereby 
considering a balanced selection of normal weight (n = 35) and 
overweight/obese (n = 35) individuals. In comparison with 
UHPLC-HRMS, a lower number of samples was included due 
to reasons of depletion. PCA-X modelling (Figure 4) indicated 
narrow clustering of the internal QC-samples and thus stable 
analytical performance. However, no differentiation according 
to weight was observed, which was confirmed by the 
subsequent OPLS-DA modelling approach (Q2 < 0.5 and CV-
ANOVA p-value > 0.05). Pre-filtering of the data based on the 
Jack-knifed confidence intervals (not across zero) and VIP-
score (≥ 1) rendered 505 ions (features), for which valid OPLS-
DA models (1 predictive and 2 orthogonal principal 
components) could be constructed (R2(X) of 0.227, R2(Y) of 
0.946, Q2 of 0.808; p-value of 9.01 e-21; good permutation 
testing) (Figure 4). Performing a fivefold 20%-leave-out 
validation strategy, the general classification accuracy was 
97.1% (sensitivity of 100% and specificity of 94.3%). As such, 
LA-REIMS fingerprinting allowed to establish predictive 
models that are able to appoint metabolic perturbations 
according to pathophysiological state (i.e. weight state), also 
offering potential to evaluate e.g. the contribution of etiological 
factors and intervention efficacy.
Figure 4. PCA-X (A) and OPLS-DA (B) score plot as obtained 
upon LA-REIMS fingerprinting of saliva from normal weight (n = 
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35, blue) and overweight/obese (n = 35, yellow) individuals. Grey 
circles in Figure A represent QC-samples.
Conclusion
Saliva represents an interesting matrix for clinical and 
epidemiological research because saliva is chemically rich, its 
collection is non-invasive and easy, multiple samples can be 
collected per day, and no highly trained personnel is needed. 
However, current methods for analysis of saliva are typically 
elaborated for targeted profiling and lacking thorough 
validation. With this study, we present a UHPLC-HRMS 
method for salivary metabolomics that was validated and 
demonstrated fit-for-purpose for profiling and fingerprinting. In 
a clinical context of overweight in adolescents, our 
methodology was able to define biologically relevant 
metabolite profiles (129 metabolites were identified, of which 
45 have been ascribed a role in obesity) and discriminative 
fingerprints (> 6,500 metabolites detected), offering potential 
for biomarker discovery and pathway elucidation. In light of 
these findings, saliva may serve as a valuable matrix for point-
of-care applications and precision medicine. Therefore, to 
translate metabolomics towards a clinical environment, we 
proposed the concept of LA-REIMS for salivary metabolomics. 
With the metabolome coverage being comparable to UHPLC-
HRMS, this ambient ionization technique also achieved 
differentiation according to weight status. In conclusion, this 
work presents a complementary platform of validated UHPLC-
HRMS and robust LA-REIMS for salivary metabolomics, 
offering opportunities for in-depth mechanistic studies and 
rapid discriminative fingerprinting, respectively. 
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Figure 1. Fingerprint of positive (A) and negative (B) component ions upon UHPLC-HRMS analysis of saliva 
from adolescents (n = 140). Identified metabolites (in-house library) are indicated in bold. 
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Figure 2. PCA-X (A) and OPLS-DA (B) score plot as obtained upon UHPLC-HRMS fingerprinting of saliva from 
normal weight (n = 41, blue) and obese/overweight (n = 41, yellow) individuals. Grey circles in Figure A 
represent QC-samples. 
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Figure 3. TIC signal (“burn”) as obtained upon LA-REIMS analysis of saliva in negative (A) and positive (C) 
ionization mode. Mass spectra for negative and positive ionization (B and D, respectively). 
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Figure 4. PCA-X (A) and OPLS-DA (B) score plot as obtained upon LA-REIMS fingerprinting of saliva from 
normal weight (n = 35, blue) and overweight/obese (n = 35, yellow) individuals. Grey circles in Figure A 
represent QC-samples. 
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